SINGULAIR is indicated for prevention of EIB in patients
aged >15 years.
In a clinical study of patients aged >15 years
SINGULAIR 10 mg prevented EIB in patients who
were challenged 2 hours postdose
In the same clinical study
81% of patients taking SINGULAIR 10 mg had a ≤20% fall in FEV1
vs 45% taking placebo at 2 hours8
SINGULAIR is the first and only oral tablet approved for prevention of EIB.
SINGULAIR is indicated for prevention of EIB in patients aged 15 years and older.
Study Design
A randomized, double-blind, placebo-controlled crossover study of 47 patients aged 15 years and older with EIB. Patients received a single dose of SINGULAIR 10 mg. Exercise challenge was performed at 2, 8.5, and 24 hours postdose.
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older and for prevention of exercise-induced bronchoconstriction (EIB) in patients aged 15 years and older.
For prevention of EIB, a single 10-mg dose of SINGULAIR should be taken at least 2 hours before exercise. An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.
Patients already taking SINGULAIR daily for another indication should not take an additional dose to prevent EIB.
SELECTED SAFETY INFORMATION
- SINGULAIR should not be used as rescue medication to treat acute asthma attacks. Patients should be advised to have appropriate rescue medication available.
- Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
- While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, SINGULAIR should not be abruptly substituted for inhaled or oral corticosteroids.
- Patients receiving SINGULAIR should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
- The most common adverse reactions with an incidence >5% and greater than placebo in controlled clinical trials were upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, and otitis.
- Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.
Before prescribing SINGULAIR, please read the Prescribing Information.
For general information and other services for physicians
SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
PRIVACY POLICY